Castleark Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Castleark Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Hold	80,890	–	–	0.34%	59
2025 Q4	$9.86M	Hold	80,890	–	–	0.29%	66
2025 Q3	$8.11M	Buy	+80,890	New	+$7.29M	0.23%	86
2025 Q1	–	Sell	-98,850	Closed	-$8.9M	–	348
2024 Q4	$8.9M	Sell	98,850 -16,730	-14%	-$1.62M	0.31%	53
2024 Q3	$11.4M	Buy	115,580 +65,490	+131%	+$6.43M	0.47%	37
2024 Q2	$4.64M	Sell	50,090 -50,090	-50%	-$4.49M	0.19%	120
2024 Q1	$9.51M	Buy	+100,180	New	+$9.3M	0.4%	46
2023 Q3	–	Sell	-143,110	Closed	-$11.9M	–	320
2023 Q2	$11.9M	Buy	+143,110	New	+$12M	0.54%	33
2023 Q1	–	Sell	-448,640	Closed	-$37.2M	–	326
2022 Q4	$37.2M	Hold	448,640	–	–	1.95%	13
2022 Q3	$35.6M	Sell	448,640 -195,250	-30%	-$16.5M	1.98%	11
2022 Q2	$47.8M	Buy	+643,890	New	+$48.3M	2.56%	8
2014 Q1	–	Sell	-19,200	Closed	-$833K	–	334
2013 Q4	$833K	Buy	19,200 +1,470	+8%	+$60.9K	0.02%	252
2013 Q3	$922K	Buy	17,730 +14,130	+393%	+$572K	0.03%	247
2013 Q2	$125K	Buy	+3,600	New	+$127K	﹤0.01%	291

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Castleark Management's XBI Position: Q1 2026 in Review

Castleark Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 80,890 shares worth $10.3M. The position accounts for 0.34% of the portfolio, ranked #59.

Castleark Management first reported a position in XBI in Q2 2013 and has held it in 14 quarters since. The position peaked at $47.8M in Q2 2022. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Castleark Management held 80,890 shares of State Street SPDR S&P Biotech ETF worth $10.3M as of Q1 2026.
Castleark Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.34% of Castleark Management's portfolio in Q1 2026, its #59 holding.
Castleark Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 14 quarters since.
Castleark Management's State Street SPDR S&P Biotech ETF position peaked at $47.8M in Q2 2022.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.